Survival Rate of Gemcitabine Monotherapy after Prior Platinum-based Chemotherapy for Metastatic Bladder Cancer
DOI:
https://doi.org/10.55175/cdk.v49i12.329Kata Kunci:
Bladder cancer, gemcitabine monotherapy, survival rateAbstrak
Background: Bladder cancer is the most common type of cancer in the urinary system and the eleventh most common cancer in the world. The overall 5-year survival of bladder cancer in metastatic stage is very low. The standard first-line chemotherapy for bladder cancer is M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) and GC (gemcitabine, cisplatin) while the second-line is vinflunine. Gemcitabine has shown a higher response rate than vinflunine as a second-line treatment. But, the overall survival-rate of gemcitabine is still unknown. Objective: To determine whether gemcitabine monotherapy can increase the survival rate in metastatic bladder carcinoma after prior platinum-based chemotherapy. Methods: A literature search was through 3 databases: Pubmed, Scopus, and Cochrane. Studies were selected based on PICO and eligibility criteria for this report. Four studies from 3 databases were selected and critically appraised using Oxford University’s Center of Evidence-Based Medicine (CEBM) form. Result: Gemcitabine monotherapy may increase the survival rate of metastatic bladder cancer patients. However, gemcitabine has several severe side effects and the validity of the studies is low. Conclusion: Gemcitabine monotherapy may increase the survival rate of metastatic bladder cancer patients, but the evidence level is low. Latar belakang: Kanker kandung kemih merupakan kanker sistem saluran kemih yang paling umum dan merupakan kanker paling umum kesebelas di dunia. Kesintasan 5 tahun kanker kandung kemih cukup tinggi, namun sangat rendah pada kondisi metastasis. Kemoterapi standar lini pertama untuk kanker kandung kemih adalah M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) dan GC (gemcitabine, cisplatin), sedangkan lini kedua adalah vinflunine. Gemcitabine sebagai pengobatan lini kedua telah menunjukkan tingkat respons lebih tinggi daripada vinflunine. Namun, kesintasan monoterapi gemcitabine sebagai terapi lini kedua setelah kemoterapi berbasis platinum secara keseluruhan masih belum diketahui. Tujuan: Mengetahui apakah monoterapi gemcitabine sebagai terapi lini kedua setelah kemoterapi berbasis platinum dapat meningkatkan tingkat kelangsungan hidup pasien kanker kandung kemih yang metastatik. Metode: Pencarian literatur menggunakan 3 database, yaitu Pubmed, Scopus, dan Cochrane. Studi dipilih berdasarkan PICO dan kriteria kelayakan yang sesuai untuk laporan ini. Empat studi terpilih dinilai secara kritis menggunakan formulir center of evidence based medicine dari Universitas Oxford. Hasil: Monoterapi gemcitabine dapat meningkatkan angka kelangsungan hidup pasien kanker kandung kemih yang mengalami metastasis. Namun, gemcitabine memiliki beberapa efek samping berat dan validitas penelitian rendah. Simpulan: Monoterapi gemcitabine dapat meningkatkan tingkat kelangsungan hidup pada pasien kanker kandung kemih metastatik, namun level of evidence rendah.
Unduhan
Referensi
Kaseb H, Aeddula NR. Bladder cancer. StatPearls Publishing [Internet]. 2021 [cited 2021 Feb 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536923/
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;8(15):1–12.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Anghel RM, Gales LN, Trifanescu OG. Outcome of urinary bladder cancer after combined therapies. J Med Life. 2016;9(1):95–100.
Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur Urol. 2011;59(6):1009–18.
Bajorin BDF, Dodd PM, Mazumdar M, Fazzari M, Mccaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.
Yaf FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol. 2011;18(1):25–34.
Akaza H, Naito S, Usami M, Miki T, Miyanaga N, Taniai H. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatincontaining therapy: A Japanese experience. Jpn J Clin Oncol. 2007;37(3):201–6.
Soga N, Kise H, Arima K, Sugimura Y. Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer. Int J Clin Oncol. 2010;15(4):376–81.
Muto S, Abe H, Noguchi T, Sho-ichiro S, Kitamura K, Isotani S, et al. Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer. Int J Urol. 2015;22(5):490–4.
Kalogirou C, Svistunov A, Krebs M, Lausenmeyer EM, Vergho D, Riedmiller H, et al. Maintenance monotherapy with gemcitabine following cisplatin-based primary combination chemotherapy in surgically treated advanced urothelial carcinoma: A matched-pair single institution analysis. Mol Clin Oncol. 2016;4(4):636–42.
Nuffield Department of Primary Care Health Sciences (Medical Sciences). Critical appraisal tools — Centre for evidence-based medicine (CEBM), University of Oxford [Internet]. 2020 [cited 2022 Aug 12]. Available from: https://www.cebm.ox.ac.uk/resources/ebm-tools/critical-appraisal-tools?7ed03f96-1a40-11ed-8e24-0a442fc5b724
Scher HI, Rosenberg JE, Motzer RJ. Bladder and renal cell carcinomas. In: Longo DL, editor. Harrison’s hematology and oncology. 3rd ed. McGraw-Hill Education; 2017. p. 582.
Thompson DB, Siref LE, Feloney MP, Hauke RJ, Agrawal DK. Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol. 2015;11(2):265–79.
Zhao M, He XL, Teng XD. Understanding the molecular pathogenesis and prognostics of bladder cancer: An overview. Chinese J Cancer Res. 2016;28(1):92–8.
El Karak F, Flechon A. Gemcitabine in bladder cancer. Expert Opin Pharmacother. 2007;8(18):3251–6.
De Sousa Cavalcante L, Monteiro G. Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16. http://dx.doi.org/10.1016/j.ejphar.2014.07.041
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
